DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction.
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Biomarkers
Biomarkers, Tumor
Biopsy
Cyclophosphamide
/ adverse effects
Doxorubicin
/ adverse effects
Etoposide
/ adverse effects
Female
Gene Rearrangement
Humans
Immunohistochemistry
In Situ Hybridization, Fluorescence
Kidney Diseases
/ complications
Kidney Function Tests
Lymphoma, B-Cell
/ complications
Male
Neoplasm Grading
Neoplasm Staging
Prednisone
/ adverse effects
Proto-Oncogene Proteins c-bcl-2
Proto-Oncogene Proteins c-bcl-6
Proto-Oncogene Proteins c-myc
/ genetics
Rituximab
/ administration & dosage
Tomography, X-Ray Computed
Treatment Outcome
Vincristine
/ adverse effects
DA-EPOCH-R therapy
double-hit lymphoma
high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
renal dysfunction
renal impairment
Journal
Journal of clinical and experimental hematopathology : JCEH
ISSN: 1880-9952
Titre abrégé: J Clin Exp Hematop
Pays: Japan
ID NLM: 101141257
Informations de publication
Date de publication:
18 Mar 2021
18 Mar 2021
Historique:
pubmed:
9
2
2021
medline:
28
5
2021
entrez:
8
2
2021
Statut:
ppublish
Résumé
High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, also known as double-hit lymphoma, has been reported as refractory to R-CHOP therapy and requires more intensive regimens. However, intensive and safe regimens for patients with renal dysfunction are unknown. Herein, we report the successful use of DA-EPOCH-R therapy for double-hit lymphoma in a 64-year-old man with renal dysfunction. The patient had lymphoma-induced bilateral ureteral obstruction. Although renal dysfunction remained after removing the obstruction using R-CHOP therapy, we completed six cycles of DA-EPOCH-R therapy without any major adverse events. DA-EPOCH-R therapy may be a safe regimen for renal dysfunction patients.
Identifiants
pubmed: 33551436
doi: 10.3960/jslrt.20043
pmc: PMC8053571
doi:
Substances chimiques
BCL2 protein, human
0
BCL6 protein, human
0
Biomarkers
0
Biomarkers, Tumor
0
Proto-Oncogene Proteins c-bcl-2
0
Proto-Oncogene Proteins c-bcl-6
0
Proto-Oncogene Proteins c-myc
0
Rituximab
4F4X42SYQ6
Vincristine
5J49Q6B70F
Etoposide
6PLQ3CP4P3
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Prednisone
VB0R961HZT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
42-47Références
J Clin Oncol. 2017 Jul 10;35(20):2260-2267
pubmed: 28475457
Blood. 2014 Oct 9;124(15):2354-61
pubmed: 25161267
Leuk Lymphoma. 2002 Sep;43(9):1783-8
pubmed: 12685832
Br J Haematol. 2019 Oct;187(2):185-194
pubmed: 31222719
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Lancet Haematol. 2018 Dec;5(12):e609-e617
pubmed: 30501868
J Clin Exp Hematop. 2016;56(2):79-88
pubmed: 27980306
Haematologica. 2009 Jul;94(7):935-43
pubmed: 19535347
J Clin Oncol. 2010 Aug 20;28(24):3880-9
pubmed: 20660823
J Pediatr Hematol Oncol. 2019 Aug;41(6):498-500
pubmed: 30095692
Ann Hematol. 2020 Aug;99(8):1823-1831
pubmed: 32577843
Leuk Lymphoma. 2014 Jun;55(6):1345-9
pubmed: 24004183
Ann Oncol. 2007 Mar;18(3):541-5
pubmed: 17164228
J Clin Exp Hematop. 2020 Jun 20;60(2):60-61
pubmed: 32404573
Blood. 2009 Oct 22;114(17):3533-7
pubmed: 19704118
Cancer. 2010 Sep 15;116(18):4283-90
pubmed: 20564149
Cancer Sci. 2016 Jun;107(6):853-61
pubmed: 27027803
Ann Oncol. 2002 Aug;13(8):1264-74
pubmed: 12181251
Blood Rev. 2006 Nov;20(6):319-32
pubmed: 16884838
Blood. 2009 Sep 10;114(11):2273-9
pubmed: 19597184
Br J Haematol. 2015 Aug;170(4):504-14
pubmed: 25907897
Blood. 2002 Apr 15;99(8):2685-93
pubmed: 11929754
Lancet Oncol. 2019 Apr;20(4):e200-e207
pubmed: 30942181